Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs
Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.
Neoadjuvant Durvalumab/Chemo, Adjuvant Durvalumab Improves EFS in Cisplatin-Eligible MIBC
Thomas Powles, MBBS, MRCP, MD, presented results from the NIAGRA trial assessing perioperative durvalumab in patients with cisplatin-eligible MIBC.
QOL, Pain Deterioration Improve With T-DXd in HER2-Low Breast Cancer
QOL data from DESTINY-Breast06 support T-DXd as a new therapeutic option in previously treated HER2-low and HER2-ultralow metastatic breast cancer.
CheckMate 77T Highlights EFS Benefit in Perioperative Nivolumab in Resectable NSCLC
A median EFS of 40.1 months was noted in patients resectable NSCLC given perioperative nivolumab vs placebo.
Hypofractionated Radiation Noninferior to Normofractionated Radiation in Early Breast Cancer
In patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.
Ramucirumab Combo Shows No Significant OS Improvement in Metastatic CRC
Subgroup analysis in a phase 3 trial show OS benefits with the ramucirumab-based regimen in female patients and those with left-sided tumors.
OS Increase Observed in Neoadjuvant Pembrolizumab Combo Plus Adjuvant Therapy in Early TNBC
A pembrolizumab regimen for patients with early-stage triple-negative breast cancer yielded improved overall survival.
Pembrolizumab Combo Shows DFS Benefit in dMMR Endometrial Cancer Subgroup
The addition of pembrolizumab to chemotherapy with or without radiation did not improve DFS across the intent-to-treat population of KEYNOTE-B21.
Superiority Noted in Adagrasib Vs Docetaxel in Patients With KRAS G12C-Mutated NSCLC
Superior efficacy outcomes were noted when adagrasib was used to treat patients with KRAS G12C NSCLC and among those with brain metastases.
rPFS/OS Benefit in Radium-223 Plus Enzalutamide in mCRPC
Significant survival benefits were observed with Radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Retifanlimab Plus Carboplatin Meets PFS End Point in Metastatic SCAC
The primary end point of progression-free survival was met with retifanlimab to carboplatin and paclitaxel in patients with metastatic SCAC.
Clinical Benefit Improves With Relatlimab Combo in Recurrent NSCLC
The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.
Pembrolizumab/CRT Improve Survival in High-Risk Locally Advanced Cervical Cancer
Pembrolizumab combination improved efficacy outcomes vs chemoradiotherapy alone in patients with advanced cervical cancer.
Neoadjuvant ET And De-Escalated Chemotherapy Lead to ‘Exceptionally Excellent’ Survival in HR+/HER+ Early Breast Cancer
Neoadjuvant endocrine therapy or paclitaxel with trastuzumab/pertuzumab elicited significant survival in HR-positive, HER2-positive early breast cancer.
TILs May Play Prognostic Role in Overall Survival in Trastuzumab Treatment of Early HER2-Positive Breast Cancer
High TILs may predict who may have a reduced risk for disease relapse or death in patients with early HER2-positive breast cancer treated with trastuzumab.
Amivantamab/Chemo Shows Sustained OS in Advanced EGFR+ NSCLC
Amivantamab plus chemotherapy also improved time to symptomatic progression among patients enrolled on the MARIPOSA-2 trial.
Belrestotug/Dostarlimab Improves ORR in PD-L1–High NSCLC
Data from the GALAXIES-Lung 201 trial found efficacy improvement in patients with advanced NSCLC.
Lenvatinib Improves Efficacy in Real-World Thyroid Cancer Settings
Patients with radioiodine-refractory differentiated thyroid cancer appear to derive benefit from lenvatinib in community and academic settings.
T-DXd Yields Enduring Intracranial Activity in HER2+ Breast Cancer
Findings from DESTINY-Breast12 support the use of T-DXd for patients with HER2-positive metastatic breast cancer.
Novel Monoclonal Antibody Combo Shows Modest PFS Benefit in Extensive-Stage SCLC
BMS-986012 in combination with nivolumab/chemotherapy showed numerical PFS improvements in those with and without brain metastases at baseline.
Addition of Capivasertib to Paclitaxel Fails to Improve OS in Metastatic TNBC
The phase 3 CAPItello-290 trial of capivasertib plus paclitaxel did not meet its primary end point of improved overall survival in the frontline setting of metastatic triple-negative breast cancer.
Belzutifan Yields Sustained Responses, PFS in Advanced Clear Cell RCC
Final analysis data from LITESPARK-005 support belzutifan as a treatment for patients with previously treated advanced clear cell RCC.
Consolidation Durvalumab Consistently Improves PFS/OS in LS-SCLC Subgroups
The magnitude of benefit with durvalumab was particularly consistent within prophylactic cranial irradiation and radiation subgroups in the ADRIATIC trial.
Adjuvant Durvalumab Does Not Improve DFS Across NSCLC PD-L1 Subgroups
Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.
Comprehensive Childhood ALL Genotyping May Optimize Risk Stratification
Genomic subtype was associated with relapse, occurring in nearly 50% of PAX5-altered pediatric acute lymphoblastic leukemia cases.
FDA Approves Subcutaneous Atezolizumab Plus Hyaluronidase-tqjs in Multiple Soft Tumor Indications
Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.
Neoadjuvant/Adjuvant Durvalumab Combo Elicits Sustained EFS in NSCLC
Updated findings from the AEGEAN trial support perioperative durvalumab as a new therapy option for those with resectable non–small cell lung cancer.
Taletrectinib Yields Intracranial Responses in Advanced ROS1+ NSCLC
Phase 2 data show meaningful efficacy with taletrectinib regardless of whether patients with ROS1-positive NSCLC previously received tyrosine kinase inhibitors.
Bria-IMT Combo Elicits Overall Survival Benefit in Metastatic Breast Cancer
Early data appear to highlight encouraging efficacy and tolerability outcomes with Bria-IMT in patients with metastatic breast cancer.
THIO Combo Yields Survival Benefit in Advanced Non–Small Cell Lung Cancer
Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial in late 2024.
